Analytical Release Testing for Viral Vectors: AAV and Lentiviral Quality Control

Viral vector release testing requires a battery of analytical methods that, for the most part, did not exist a decade ago, and the regulatory bar rises with every new gene therapy approval. For adeno-associated virus (AAV) and lentiviral vectors, demonstrating batch quality demands orthogonal assays covering titer, capsid content, purity, safety, and potency. Each carries distinct validation requirements that have grown substantially more specific as the field matures.

Critical quality attributes for AAV and lentiviral vector release

Viral vector release testing is organized around critical quality attributes (CQAs), the measurable characteristics that define whether a batch is safe and efficacious for clinical use. Regulatory agencies, including the FDA and the European Medicines Agency, require sponsors to establish acceptance criteria for each attribute, drawing on ICH Q6B and product-specific gene therapy guidance. For both AAV and lentiviral vectors, the relevant categories are identity, purity, potency, safety, and quantity, though the specific assays differ substantially between the two platforms.

The complexity of vector QC arises because no single assay can simultaneously confirm identity, quantify genome content, assess capsid integrity, and verify biological activity. Release panels for commercial-stage products routinely involve ten or more individual tests, with multiple orthogonal methods required for the most safety-critical attributes. The FDA CGT potency guidance, alongside the EMA's ICH Q6B framework, provides the overarching specification logic for both modalities.

Table 1. Core release testing categories for AAV and lentiviral vectors, with principal analytical methods used at the lot release stage.

AAV and lentiviral genome titer: ddPCR vs qPCR

Accurate genome titer underpins viral vector release testing because both preclinical and clinical dosing are expressed in vector genomes per kilogram. Quantitative PCR (qPCR) was historically the standard, but droplet digital PCR (ddPCR) has progressively displaced it for AAV and lentiviral programs. Research comparing ddPCR with qPCR for AAV characterization confirms that ddPCR delivers superior intra- and inter-assay precision, lower coefficient of variation, and greater resistance to PCR inhibitors, advantages especially relevant for in-process samples of varying purity.

ddPCR partitions reactions into approximately 20,000 nanoliter droplets, applying Poisson statistics to return an absolute copy number without relying on a standard curve. However, ddPCR performance is sensitive to sample preparation: capsid lysis protocol, DNase I digestion duration, and dilution buffer composition all affect measured titer, and inter-instrument variability across ddPCR platforms can be substantial without standardized pre-treatment. For lentiviral vectors, infectious titer uses cell transduction followed by PCR quantification of vector copy number in target cells, adding complexity given the integration step unique to the retroviral life cycle.

AAV full/empty capsid ratio: analytical methods and residual impurity testing

The ratio of genome-containing (full) to empty capsid particles is a critical quality attribute unique to AAV. Empty capsids cannot deliver a therapeutic gene, may increase immunogenicity, and dilute the effective dose. A review of AAV characterization methods in Molecular Therapy: Methods & Clinical Development identifies the full/empty ratio as requiring highly precise orthogonal measurement, noting that current platforms vary substantially in throughput, sample volume requirements, and resolution for partial capsid species.

Analytical ultracentrifugation (AUC), specifically sedimentation velocity AUC, is the benchmark method with an established regulatory history in AAV submissions. It resolves empty, partial, and full populations based on sedimentation coefficient differences, but requires several hours per sample and up to 500 µL of purified product. Mass photometry has emerged as a complementary approach: mass photometry studies for AAV show it can resolve capsid populations across multiple serotypes with far smaller sample volumes and analysis times of minutes, making it useful for process development and increasingly viable for release testing when combined with AUC.

Residual host cell DNA and host cell proteins (HCPs) are mandatory impurity tests at lot release. Host cell DNA is quantified by qPCR or ddPCR targeting repetitive genomic sequences such as the 18S ribosomal RNA gene, with results expressed as picograms per dose. HCP quantification relies on sandwich ELISA using polyclonal antisera raised against production cell line proteins, validated for high sensitivity in the low ng/mL range; mass spectrometry is increasingly used as an orthogonal tool to confirm antibody coverage and identify high-risk individual proteins.

Replication-competent virus testing and viral vector potency assays

Safety testing addresses the potential presence of replication-competent virus. For lentiviral vectors, replication-competent lentivirus (RCL) is assessed via cell-based amplification assays followed by PCR confirmation, as required by the FDA's retroviral vector testing guidance. A retrospective review of 460 T cell products from 26 clinical trials found no product RCL-positive, supporting the biosafety of current self-inactivating vector designs. For AAV, helper virus clearance must be confirmed, with specific analytes dependent on the production system.

Potency is the most scientifically complex element of the release panel. Under FDA and EMA expectations, potency assays must be quantitative and mechanism-of-action-based. A review of CGT potency assay requirements notes that cell-based assays are most commonly used, with in vivo models impractical for routine lot release. For AAV therapies, this typically means a cell transduction assay quantifying transgene-encoded protein in a target cell line calibrated against a reference standard; for lentiviral ex vivo programs, vector copy number in transduced cells serves as a surrogate alongside functional cell activity assays.

Viral vector release testing at scale: building a fit-for-purpose QC strategy

Viral vector release testing programs must balance analytical rigor with operational practicality at clinical and commercial scales. The ongoing maturation of faster platforms (ddPCR for titer, mass photometry for capsid content), alongside growing regulatory acceptance of both methods, is making thorough characterization more achievable within manufacturing timelines. The mass spectrometry and proteomics workflows used in the broader analytical characterization of biologics are increasingly informing gene therapy QC strategies, particularly for HCP identification and capsid proteomics.

The connection between viral vector QC and the broader bioprocessing quality framework underscores that robust release testing is inseparable from upstream process control. As process analytics and QC infrastructure continue to mature across biomanufacturing, gene therapy programs stand to benefit substantially from the analytical frameworks being developed in parallel.

This content includes text that has been created with the assistance of generative AI and has undergone editorial review before publishing. Technology Networks' AI policy can be found here.